Medicine and Dentistry
Randomized Controlled Trial
100%
Dipeptidyl Peptidase-4 Inhibitor
100%
Hypoglycemia
40%
Maturity Onset Diabetes of the Young
40%
Cardiovascular System
40%
Clinical Study
20%
Cardiovascular Disease
20%
General Medicine
20%
Hyperglycemia
20%
Adverse Event
20%
Congestive Heart Failure
20%
Clinical Trial
20%
Nephropathy
20%
Glycemic Control
20%
Chronic Kidney Disease
20%
Cardiovascular Risk
20%
Metabolic Disorder
20%
Awareness
20%
Keyphrases
Dipeptidyl peptidase-4 (DPP-4)
100%
Randomized Controlled Trial
100%
Hypoglycemia Risk
12%
Heart Failure Hospitalization
12%
Raising Awareness
12%
Type 2 Diabetes Mellitus (T2DM)
12%
Adverse Events
12%
Hypoglycemia
12%
Chronic Kidney Disease
12%
Glycemic Control
12%
Renal Impairment
12%
Cardiovascular Safety
12%
Hyperglycemia
12%
Non-associated
12%
Type 2 Diabetes Mellitus Patients
12%
Phase III Clinical Trial
12%
General Practice
12%
Cardiovascular Outcome Trials
12%
In-hospital Management
12%
Established Cardiovascular Disease
12%
Outcome Trials
12%
Insulin
12%
Metabolic Disorders
12%
Cardiovascular Risk
12%
Safety Outcomes
12%
Pharmacology, Toxicology and Pharmaceutical Science
Randomized Controlled Trial
100%
Dipeptidyl Peptidase IV Inhibitor
100%
Hypoglycemia
40%
Non Insulin Dependent Diabetes Mellitus
40%
Clinical Study
20%
Chronic Kidney Failure
20%
Cardiovascular Risk
20%
Cardiovascular Disease
20%
Adverse Event
20%
Kidney Disease
20%
Clinical Trial
20%
Hyperglycemia
20%
Congestive Heart Failure
20%